Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment
Mandate

Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment

July 12, 2019 Capital Markets and Public M&A

The Norwegian energy company Equinor ASA announced on 7 July that it had agreed with Lundin Petroleum AB (publ) to divest around 54.5 million shares in Lundin Petroleum for a total consideration of around USD 1.56 billion and to acquire 2.6% of the development project Johan Sverdrup for a cash consideration of USD 910 million.  

Equinor ASA is a global energy company with more than 20,000 employees and business in more than 30 countries. Equinor is the largest oil and gas operator in Norway, one of the largest offshore operators globally and has a growing portfolio of renewable assets in wind and solar power.
 
Vinge’s team consisted of Dain Hård Nevonen, David Andersson, Johan Karlsson och Anna Grigorian.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024